Elisa Holmlund-Suila

Elisa Holmlund-Suila

Auto-generated profile, based on publicly available information

Elisa Holmlund-Suila

Children’s Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital , Helsinki , Finland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
MEMaria Enlund-Cerullo
Maria Enlund-Cerullo
LKLaura Koljonen
Laura Koljonen
EHElisa Holmlund-Suila
Elisa Holmlund-Suila
HHHelena Hauta-alus
Helena Hauta-alus
JRJenni Rosendahl
Jenni Rosendahl
MPMinna Pekkinen
Minna Pekkinen
Context: Single nucleotide polymorphisms (SNPs) of the vitamin D binding protein encoding the GC (group component) gene affect 25-hydroxyvitamin D (25OHD) concentrations, but their influence on vitamin D status and response to vitamin D supplementation in infants is unknown.Objective: To study GC genotype–related differences in 25OHD concentrations and the response to supplementation during a vitamin D intervention study in infants.Design: In this randomized controlled trial, healthy term infants received vitamin D3 (10 or 30 μg/d) from 2 weeks to 24 months of age. GC SNPs rs2282679, rs4588, rs7041, and rs1155563 were genotyped. rs4588/7041 diplotype and haplotypes of rs2282679, rs4588, and rs7041 (Haplo3SNP) and of all four SNPs (Haplo4SNP) were determined.Main Outcome Measures: 25OHD measured in cord blood at birth and at 12 and 24 months during intervention.Results: A total of 913 infants were included. Minor allele homozygosity of all studied GC SNPs, their combined haplotypes, and rs4588/rs7041 diplotype 2/2 were associated with lower 25OHD concentrations at all time points in one or both intervention groups [analysis of covariance (ANCOVA) P < 0.043], with the exception of rs7041, which did not affect 25OHD at birth. In the high-dose supplementation group receiving 30 μg/d vitamin D3, but not in those receiving 10 µg/d, genotype of rs2282679, rs4588, and rs7041; diplotype; and Haplo3SNP significantly affected intervention response (repeated measurement ANCOVA Pinteraction < 0.019). Minor allele homozygotes had lower 25OHD concentrations and smaller increases in 25OHD throughout the intervention.Conclusions: In infants, vitamin D binding protein genotype affects 25OHD concentration and efficiency of high-dose vitamin D3 supplementation.

16 December 2019 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
AKAnders Kämpe
Anders Kämpe
MEMaria Enlund-Cerullo
Maria Enlund-Cerullo
SVSaara Valkama
Saara Valkama
EHElisa Holmlund-Suila
Elisa Holmlund-Suila
JRJenni Rosendahl
Jenni Rosendahl
OMOuti Mäkitie
Outi Mäkitie
Vitamin D is important for normal skeletal homeostasis, especially in growing children. There are no previous genome-wide association (GWA) studies exploring genetic factors that influence vitamin D metabolism in early childhood. We performed a GWA study on serum 25-hydroxyvitamin D (25(OH)D) and response to supplementation in 761 healthy term-born Finnish 24-month-old children, who participated in a randomized clinical trial comparing effects of 10 μg and 30 μg of daily vitamin D supplementation from age 2 weeks to 24 months. Using the Illumina Infinium Global Screening Array, which has been optimized for imputation, a total of 686085 markers were genotyped across the genome. Serum 25(OH)D was measured at the end of the intervention at 24 months of age. Skeletal parameters reflecting bone strength were determined at the distal tibia at 24 months using peripheral quantitative computed tomography (pQCT) (data available for 648 children). For 25(OH)D, two strong GWA signals were identified, localizing to GC (Vitamin D binding protein) and CYP2R1 (Vitamin D 25-hydroxylase) genes. The GWA locus comprising the GC gene also associated with response to supplementation. Further evidence for the importance of these two genes was obtained by comparing association signals to gene expression data from the Genotype-Tissue Expression project and performing colocalization analyses. Through the identification of haplotypes associated with low or high 25(OH)D concentrations we used a Mendelian randomization approach to show that haplotypes associating with low 25(OH)D were also associated with low pQCT parameters in the 24-month-old children. In this first GWA study on 25(OH)D in this age group we show that already at the age of 24 months genetic variation influences 25(OH)D concentrations and determines response to supplementation, with genome-wide significant associations with GC and CYP2R1. Also, the dual association between haplotypes, 25(OH)D and pQCT parameters gives support for vertical pleiotropy mediated by 25(OH)D. The effect of vitamin D continues to be highly debated in various health outcomes, including bone health. In this study first study of children this young we searched for genes that modify vitamin D metabolism in early childhood using a genome-wide analysis of almost 700,000 genetic variants in a cohort of 761 healthy children participating in a vitamin D intervention study. We show that genetic variation in the genes coding for Vitamin D binding protein (GC) and Vitamin D 25-hydroxylase (CYP2R1) are important determinants for serum 25-hydroxyvitamin D concentration in 2-year-old children. Genetic variants within the GC gene also affect how the child responds to vitamin D supplementation. Moreover, our findings suggest that in 2-year-old children vitamin D concentration, even when within the normal range, influences bone strength as children with genetic constellations associating with lower vitamin D concentration and poorer response to vitamin D supplementation also have weaker bones.

1 February 2022 in Clinical Nutrition
Verified
Journal Article
Open access
EHElisa M. Holmlund-Suila
Elisa M. Holmlund-Suila
HHHelena Hauta-alus
Helena Hauta-alus
MEMaria Enlund-Cerullo
Maria Enlund-Cerullo
JRJenni Rosendahl
Jenni Rosendahl
SVSaara M. Valkama
Saara M. Valkama
OMOuti Mäkitie
Outi Mäkitie
During early childhood the risk of iron deficiency (ID) is high. Serum ferritin serves as a marker of iron status. We explored prevalence of ID and iron deficiency anemia (IDA), and identified determinants of iron status in infants and toddlers. We performed a secondary analysis of the Vitamin D intervention in infants (VIDI) study in Finnish healthy term infants. According to study protocol, at 12- and 24-months of age iron status, growth and dietary intakes were evaluated. ID was defined as serum ferritin <10 μg/L and IDA as serum ferritin <10 μg/L and Hb <112 g/L. For the present study, altogether 766 children provided data (N = 498 infants at 12 months, N = 508 toddlers at 24 months). ID prevalence increased from 14% in infants to 20% in toddlers. IDA prevalence was 3% at both time points. In infants, ID and IDA were more common in boys than in girls (19% vs. 9%, p = 0.001 and 5% vs. 1%, p = 0.039) but no sex-difference in toddlers was observed. Of infants, 30% had daily iron intake below average requirement of 5 mg/day. Higher daily iron intake per body weight (mg/kg) independently associated with higher infant serum ferritin (B (95% CI) 0.30 (0.04, 0.56), p = 0.026). Correlation between iron intake and ferritin was stronger in infants with ID than in infants without ID. Breastfeeding was more common (63% vs. 35%, p < 0.001) among ID infants than in infants without ID. In toddlers, frequent consumption of milk products independently associated with lower ferritin (B (95% CI) -0.03 (-0.05, -0.01), p = 0.001). Consumption of meat and fish associated with better iron status. Serum ferritin at both time points associated with duration of gestation and growth. The association of growth and ferritin was age-dependent in boys, while in girls, faster growth associated consistently with lower ferritin. In Northern European healthy infants and toddlers ID is common. The intake of iron remains below recommendations and food consumption and iron intake associate with iron status. Further studies are warranted to assess significance of ID on child development and clinical health outcomes. The project protocol is registered at ClinicalTrials.gov: NCT01723852.

5 October 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
EHElisa Holmlund-Suila
Elisa Holmlund-Suila
MEMaria Enlund-Cerullo
Maria Enlund-Cerullo
SVSaara Valkama
Saara Valkama
HHHelena Hauta-Alus
Helena Hauta-Alus
JRJenni Rosendahl
Jenni Rosendahl
OMOuti Mäkitie
Outi Mäkitie
Context Fibroblast growth factor 23 (FGF23) plays an important role in phosphate homeostasis, but its regulation is inadequately characterized. Objective To examine FGF23 regulators, especially sex and iron status, in early childhood. Design A cross-sectional study involving 1-year-old children. Setting and Participants Healthy term infants with a birth weight appropriate for gestational age were recruited to an ongoing vitamin D trial at Kätilöopisto Maternity Hospital, Helsinki, Finland. At 12-month follow-up visits, serum FGF23, 25-hydroxyvitamin D (25OHD), phosphate, ionized calcium, parathyroid hormone, and iron status were measured. All 721 children (51% girls) with complete data were included. Main Outcome Measures Intact and C-terminal FGF23 concentrations and iron status at 1 year of age. Results Intact FGF23 was greater in girls than in boys [median, 44.4 pg/mL; interquartile range (IQR), 36.8 to 51.9; median, 40.9 pg/mL; IQR, 34.5 to 49.0, respectively; P < 0.001]. C-terminal FGF23 was similar in boys and girls (median, 2.8 pmol/L; IQR, 2.1 to 3.7; median, 2.9 pmol/L; IQR, 2.2 to 3.7, respectively; P = 0.393). The iron concentration was positively associated with intact FGF23 and was the strongest modifier of intact FGF23 (regression coefficient, 0.498; 95% confidence interval, 0.333 to 0.663; P < 0.001) with ferritin, season, ionized calcium, 25OHD, and sex as other covariates. The association between iron and C-terminal FGF23 was inversely related (regression coefficient, −0.072; 95% confidence interval, −0.092 to −0.051; P < 0.001). Conclusions At 1 year of age, FGF23 status was different in girls and boys, with intact FGF23 concentrations higher in girls. Iron modified FGF23 concentrations, with intact FGF23 higher and C-terminal lower, in those with greater iron concentrations.

21 December 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
HHHelena Hauta-alus
Helena Hauta-alus
EHElisa M Holmlund-Suila
Elisa M Holmlund-Suila
EKEero Kajantie
Eero Kajantie
JRJenni Rosendahl
Jenni Rosendahl
SVSaara M Valkama
Saara M Valkama
OMOuti Mäkitie
Outi Mäkitie
Context The relationship between maternal and infant vitamin D and early childhood growth remains inadequately understood. Objective To investigate how maternal and child 25-hydroxyvitamin D [25(OH)D] and vitamin D supplementation impact growth during the first 2 years of life. Design A randomized, double-blinded intervention study. Setting A single-center study from pregnancy until offspring age 2 years. Participants Altogether 812 term-born children with complete data, recruited at Maternity Hospital. Intervention Children received daily vitamin D3 supplementation 10 μg (Group-10) or 30 μg (Group-30) from age 2 weeks to 2 years. Main outcome measures Anthropometry and growth rate at age 1 and 2 years. Results Toddlers born to mothers with Pregnancy 25(OH)D >125 nmol/L were at 2 years lighter and thinner than the reference group with 25(OH)D 50-74.9 nmol/L (P<0.010). Mean 2-year 25(OH)D concentrations were 87 nmol/L in Group-10 and 118 nmol/L in Group-30 (P0.053), but Group-30 had slower growth in length and head circumference between 6 months and 1 year (P<0.047), and more rapid growth in weight and length-adjusted weight between 1 and 2 years (P121 nmol/L) were shorter (mean difference 0.2 SD score (SDS), P=0.021), lighter (mean difference 0.4 SDS, P=0.001) and thinner (in length-adjusted weight) (mean difference 0.4 SDS, P=0.003) compared with the lowest quartile (<81.2 nmol/L). Conclusion Vitamin D and early childhood growth may have an inverse U-shaped relationship.

2 July 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LKLaura Koljonen
Laura Koljonen
MEMaria Enlund-Cerullo
Maria Enlund-Cerullo
HHHelena Hauta-alus
Helena Hauta-alus
EHElisa Holmlund-Suila
Elisa Holmlund-Suila
SVSaara Valkama
Saara Valkama
OMOuti Mäkitie
Outi Mäkitie
Context Phosphate homeostasis and its modifiers in early childhood are inadequately characterized. Objective To determine physiological plasma phosphate concentration and modifying factors in healthy infants at 12 to 24 months of age. Design This study included 525 healthy infants (53% girls), who participated in a randomized vitamin D intervention trial and received daily vitamin D3 supplementation of either 10 or 30 μg from age 2 weeks to 24 months. Biochemical parameters were measured at 12 and 24 months. Dietary phosphate intake was determined at 12 months. Main Outcome Measures Plasma phosphate concentrations at 12 and 24 months of age. Results Mean (SD) phosphate concentration decreased from 12 months (1.9 ± 0.15 mmol/L) to 24 months (1.6 ± 0.17 mmol/L) of age (P < 0.001 for repeated measurements). When adjusted by covariates, such as body size, creatinine, serum 25-hydroxyvitamin D, intact and C-terminal fibroblast growth factor 23, mean plasma phosphate was higher in boys than girls during follow-up (P = 0.019). Phosphate concentrations were similar in the vitamin D intervention groups (P > 0.472 for all). Plasma iron was associated positively with plasma phosphate at both time points (B, 0.006 and 0.005; 95% CI, 0.004-0.009 and 0.002-0.008; P < 0.001 at both time points, respectively). At 24 months of age, the main modifier of phosphate concentration was plasma creatinine (B, 0.007; 95% CI 0.003-0.011, P < 0.001). Conclusion Plasma phosphate concentration decreased from age 12 to 24 months. In infants and toddlers, the strongest plasma phosphate modifiers were sex, iron, and creatinine, whereas vitamin D supplementation did not modify phosphate concentrations.